The added benefit of a dedicated neck F-18 FDG PET-CT imaging protocol in patients with suspected re
June 28th, 2008 | by admin |The added benefit of a dedicated neck F-18 FDG PET-CT imaging protocol in patients with suspected recurrent differentiated thyroid carcinoma.
PURPOSE: To retrospectively analyze whether adding a delayed high-resolution dedicated neck F-18 FDG positron emission tomography-computerized tomographic (PET-CT) imaging protocol in patients with recurrent differentiated thyroid cancer increases the number of abnormal foci within the neck. MATERIALS AND METHODS: Seventeen PET-CT studies from a total of 10 patients with suspected recurrent differentiated thyroid cancer between March 2003 and June 2004 were retrospectively reviewed. Each study included a whole body acquisition (WBA), followed by higher resolution dedicated neck acquisition (DNA). Two board-certified nuclear medicine physicians reviewed either the DNA or WBA for each study and recorded the number of abnormal foci, along with presence or absence of a soft tissue abnormality, and maximum standardized uptake value for each foci. Consensus review was used for all discrepancies. Statistical analysis was performed to determine whether there was a statistically significant increase in the number of studies demonstrating new abnormal foci with the addition of a DNA. RESULTS: Five of 17 studies demonstrated an increase in the number of abnormal foci with the addition of the DNA (P < 0.04). A total of 8 abnormal foci were noted on the WBA, 4 of which were within the neck. Eleven additional abnormal foci were seen on the DNA. All abnormal foci within the neck had corresponding soft tissue abnormalities except for one. CONCLUSION: Adding a higher resolution delayed DNA to the WBA for patients undergoing PET-CT imaging to detect recurrent thyroid cancer increases the number of abnormal sites of FDG accumulation.
Davison JM, Stocker DJ, Montilla-Soler JL, Jurgens JS, Allen TW, Holley TS, Stack AL.
Department of Radiology, Walter Reed Army Medical Center, Nuclear Medicine Clinic, Washington, DC 20307, USA. jonathan.davison@gmail.com